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 Background: Imiquimod, an immune response modifi er that 
is used topically to treat different types of skin cancer,  induces 
the  production of proinfl ammatory cytokines that stimulate 
an antitumor immune response. We assessed characteristics 
of the imiquimod-induced immune activation in epithelial and 
lymphoproliferative neoplasias of human skin. We  focused on 
plasmacytoid predendritic cells (PDCs), the primary  producer 
of interferon  α (IFN- α ) after imiquimod  activation in vitro. 
 Methods: We used Affymetrix oligonucleotide arrays to com-
pare gene expression profi les from tumors from 16  patients, 
10 with superfi cial basal cell carcinomas (sBCCs), fi ve with 
cutaneous T-cell lymphomas (CTCLs), and one with Bowen’s 
disease, before and after topical  imiquimod treatment. We 
used quantitative immunohistochemistry with PDC-specifi c 
antibodies against BDCA-2 and CD123 to  characterize the 
PDC population before and after imiquimod treatment in 
these specimens. Activation status of PDCs from four sBCC 
patients was assessed by intracellular IFN- α staining and fl ow 
cytometry.  Results: Expression of various IFN- α – inducible 
genes (e.g., CIG5, G1P2, OASL, IFIT1, STAT1, IFI35, OAS1, 
ISG20, MxA, and IRF7), the so-called IFN- α signature, was 
increased similarly in both sBCC and CTCL lesions after 
 imiquimod treatment. PDCs were  recruited and activated 
in both lesion types, and they produced IFN- α after imiqui-
mod treatment in vivo (mean percentage of PDCs  producing 
IFN- α = 14.5%, 95% confi dence interval [CI] = 4.9% to 24%; 
range = 3.3%–27%,  n = 4 lesions). Imiquimod induced similar 
 immune activation patterns in all three diseases, and these 
patterns were associated with the number of PDCs recruited 
to the treatment site. Two imiquimod-treated sBCC patients 
who did not mount an infl ammatory response to imiquimod 
and whose lesions lacked the IFN- α signature after treatment 
had fewer PDCs in treated lesions compared with other  treated 
patients with such a response.  Conclusions: Imiquimod 
 induces immune activation patterns that relate to the number 
of the PDCs  recruited to the treatment site, thus supporting 
the role of PDC in responsiveness to imiquimod in humans. 
[J Natl  Cancer Inst 2005;97:1143 – 53]
 Dendritic cells are a heterogeneous group of antigen- presenting 
cells that link innate and adaptive immunity  ( 1 , 2 ) . In humans, 
different subsets of dendritic cells have been described, some 
with a preference for specifi c organs  ( 1 , 3 ) . Among these subsets, 
epidermal Langerhans cells and dermal dendritic cells are the 
resident dendritic cell populations in human skin. Plasmacytoid 
predendritic cells (PDCs) are a newly identifi ed subset of 
 dendritic cells that are found in blood and secondary lymphoid 
organs  ( 4 ) . PDCs are characterized by a plasma cell – like 
 morphology, a unique surface phenotype (CD4 + , CD11c − , 
CD123 + , BDCA-2 + , and HLA-DR + ), and the lack of common 
lineage markers (such as CD3 on T cells, CD14 on monocytes, 
CD16 and CD56 on natural killer cells, and CD19 and CD20 on 
B cells)  ( 5 ) . PDCs represent a key component in innate antiviral 
immunity because of their capacity to produce large amounts of 
IFN- α  ( 6 , 7 ) . PDCs have also been described in lesions of infl am-
matory diseases of the skin (e.g., psoriasis vulgaris, contact 
 dermatitis, and lupus erythematosus) but are essentially absent 
in normal skin  ( 8 – 11 ) . 
 Imidazoquinolines are a group of low molecular weight 
 synthetic compounds that are potent inducers of IFN- α in vivo. 
One imidazoquinoline, imiquimod, has potent antiviral and anti-
tumor activity  ( 12 ) . By using high-throughput gene expression 
profi ling, we have recently described a group of IFN- α -inducible 
genes (e.g., IRF7, OAS1, OAS2, MxA, MxB, IFI44, IFIT1, 
IFI35, and G1P2), the so-called IFN- α signature, whose expres-
sion was increased after topical imiquimod treatment of skin 
 cancer  ( 17 ) . Imiquimod directly activates innate immune effec-
tors through a Toll-like receptor (TLR) 7/MyD88-dependent 
pathway  ( 13 ) . Through the induction of the surface expression of 
costimulatory molecules (such as CD80 and CD86) and through 
the production and release of specifi c cytokines (especially 
IFN- α , tumor necrosis factor  α , and interleukin 12), imiquimod-
treated dendritic cells induce T helper type 1 immunity  ( 13 , 14 ) . 
In vitro, blood PDCs are the principal source of IFN- α produced in 
 response to imiquimod  ( 15 ) . Topical treatment with  imiquimod 
induces several types of skin cancer to regress  ( 16 ) . However, to 
date, PDCs have not been shown to play a direct role in the 
 infl ammatory response of imiquimod-treated human neoplastic 
skin lesions. 
 In this study, we compared gene expression profi les in lesions 
before and after topical imiquimod treatment of patients with a 
neoplastic epithelial disease, superfi cial basal cell carcinoma 
(sBCC) and Bowen’s disease, or a lymphoproliferative disease of 
the skin, cutaneous T-cell lymphoma (CTCL). Because PDCs are 
considered the primary source of IFN- α after they are activated 
with imiquimod, we also assessed changes, before and  after 
 imiquimod treatment, in the PDC population in lesions from 
 patients with these two diseases. 
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 P ATIENTS AND M ETHODS 
 Patient Samples 
 We used tissue samples from patients participating in two 
clinical open-label studies that investigated the immunohistology 
and gene expression profi le of skin lesions treated with a 5% 
 imiquimod cream (Aldara, 3M Pharmaceuticals, Saint Paul, 
MN): Study 1  ( 17 ) included fi ve  patients with sBCC and one 
patient with Bowen’s disease. Study 2 included fi ve patients with 
sBCC and fi ve patients with CTCL. Both studies were approved 
by the institutional ethics committee. Before entering either 
study, patients provided written informed consent. At the screen-
ing visit that took place 2 weeks before treatment initiation, a 
biopsy specimen was taken for histologic confi rmation of sBCC 
in study 1 or for confi rmation of sBCC or CTCL in study 2. In 
study 2, a patient with CTCL was eligible if he or she had biopsy-
proven stage Ib – IIa CTCL. In study 1,  patients applied  imiquimod 
to the target sBCC lesion once daily until the treated tumor 
showed signs of erosion (generally in 3 – 5 days), and in study 2, 
patients applied imiquimod to the target sBCC or CTCL lesions 
once daily for 5 days. In study 1, surgical excision of the treated 
sBCC was performed 3 – 5 days after treatment initiation, whereas 
in study 2 the treated lesion was either completely excised (sBCC) 
or subjected to biopsy  examination (CTCL) 5 days after  treatment 
initiation. Every pre- and posttreatment tissue sample was  divided 
in two parts — one half was immediately snap frozen and stored 
at  − 80 °C, and the other half was fi xed in formalin and subse-
quently embedded in paraffi n. If the excised tumor was large 
enough, a piece of fresh tissue material was processed to obtain 
single-cell suspensions. 
 Gene Expression Profi ling 
 Total RNA was isolated from tissues by use of the TRIzol 
 reagent (Invitrogen AG, Basle, Switzerland). Double-stranded 
cDNA was generated with a cDNA synthesis kit (MessageAmp, 
Ambion Inc., Huntingdon, UK) and a (dT) 24  primer containing a 
T7 RNA polymerase promoter at the 3 ′ end. Labeled comple-
mentary RNA (cRNA) was prepared from double-stranded cDNA 
by in vitro transcription with a T7 polymerase in a reaction 
 mixture containing biotin-11-cytidine triphosphate and biotin-
16-uridine triphosphate (Enzo Diagnostics, Farmingdale, NY), 
and cRNA was purifi ed with RNA clean-up columns according
to the manufacturer’s recommendations (MessageAmp Kit). 
 Biotinylated cRNA (15  μ g) was fragmented and hybridized to 
HG-U95Av2 GeneChip arrays (Affymetrix, Santa Clara, CA) 
containing probe sets representing approximately 12  000 genes. 
Chips were hybridized, washed, and stained according to proto-
cols recommended by Affymetrix. The overall fl uorescence 
 intensity was scaled to a global intensity of 500 to enable the 
comparison between chips. 
 Raw data were imported in GeneSpring, version 7.2, microar-
ray data analysis software (Silicon Genetics, Redwood City, CA). 
The following criteria were used to select differentially regulated 
genes in imiquimod-treated versus untreated specimens during 
microarray data analysis: 1) a paired Student’s  t test with 
 Benjamini – Hochberg multiple-testing correction and a statistical 
signifi cance level at  P <.05; 2) more than a twofold change in 
 either  direction; 3) a detection  “ present ” call that coincided with 
the regulation in question — e.g., if a candidate gene was called 
 “ up-regulated ” in imiquimod-treated samples, at least one of the 
samples in the treated group had to be called  “ present ” ; and vice 
versa, if a gene was called  “ down-regulated, ” at least one of 
the samples in the untreated group had to be called  “ present. ” 
The selected differentially expressed genes were normalized to 
a mean of 0 and a standard deviation of 1, log 2 -transformed, and 
subjected to average-linkage hierarchical clustering by use of the 
uncentered Pearson similarity matrix. Clustering analysis was 
performed with the Gene Cluster program, and the display of the 
rearranged data was generated with the TreeView program  ( 18 ) 
(both programs are available through  http://rana.lbl.gov ). The 
 selected genes were annotated by use of the NetAffx Internet 
analysis system (Affymetrix)  ( 19 ) . 
 Real-Time Polymerase Chain Reaction 
 Approximately 1  μ g of total RNA was reverse transcribed with 
the 1st Strand cDNA Synthesis Kit for real-time polymerase chain 
reaction (PCR) (Roche Diagnostics AG, Rotkreutz, Switzerland) 
at 42 °C for 1 hour. PCR amplifi cations were carried out with 
the HotStart system (LightCycler – Faststart DNA Master SYBR 
Green I, Roche Diagnostics). The following primer sets were 
used: IRF7 (forward) = 5 ′ -CAAGTGCAAGGTGTACTGG-3 ′ and 
IRF7 (reverse) = 5 ′ -CAGGTAGATGGTATAGCGTGG-3 ′ ; MxA 
(forward) = 5 ′ -ACTCTGTCCAGCCCCGTAGAC-3 ′ and MxA 
(reverse) = 5 ′ -TCACAGCTTCCTGCTAAATCACC-3 ′ ; forward 
and reverse primers for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were from a GAPDH quantifi cation kit (Search 
LC, GmbH, Dossenheim, Germany). To generate external stan-
dards for subsequent quantifi cation, PCR products were purifi ed 
and cloned into the pCRII-TOPO vector with the TOPO TA 
 Cloning Kit (Invitrogen AG), according to the manufacturer’s 
 recommendations. Incorporation of the insert into the vector was 
confi rmed by sequencing, and the insert’s identity was confi rmed 
with the BLAST online program ( http://www.ncbi.nlm.nih.gov/
BLAST ). 
 Immunohistochemistry and Confocal Laser-Scanning 
Microscopy 
 Paraffi n-embedded and acetone-fi xed frozen tissue sections 
from the patients in our study were stained by use of the alkaline 
phosphatase – anti-alkaline phosphatase technique. Unspecifi c 
Fc receptor binding of antibodies used in this study was mea-
sured with isotype-matched control antibodies. The following 
 antibodies were used only on frozen tissue sections: anti-BDCA-2 
(clone AC144, Miltenyi Biotec, Bergisch Gladbach, Germany), 
anti-CD1c (L161, Immunotech, Marseilles, France), fl uorescein 
 isothiocyanate (FITC)-conjugated polyclonal rabbit anti-mouse 
immunoglobulins (DakoCytomation AG, Zug, Switzerland), and 
phycoerythrin-conjugated anti-CD123 and  allophycocyanin-
 conjugated anti-CD4 antibodies (both from BD Biosciences, 
 Basel, Switzerland). We also used anti-CD123 (7G3, BD 
 Biosciences) and anti-MxA  ( 20 ) (clone CL143) antibodies for 
paraffi n-embedded tissue sections. Quantifi cation of immunohis -
tochemical staining was performed by two independent investi-
gators who evaluated three random ×40 microscopic fi elds. 
Be cause imiquimod treatment results in an infl ux of infl amma-
tory cells at the treatment site  ( 21 , 22 ) , we evaluated the density 
of recruited  infl ammatory cells. The density of infl ammatory 
 infi ltrated cells, if present, was scored by infi ltrate density grade 
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as follows: grade 1 = mild, superfi cial, and subepidermal infi l-
trate without the  tendency to confl uence; grade 2 = moderate 
band-like infi ltrate homogeneously distributed in the papillary 
 dermis; and grade 3 = heavy infi ltrate diffusely extending to 
 reticular dermis or into the hypodermis. 
 Flow Cytometry Analysis of Ex Vivo PDCs 
 A portion of the skin biopsies obtained from study participants 
after imiquimod treatment was treated with dispase II (Roche 
 Diagnostics) overnight at 4 °C to separate epidermis from dermis. 
Dermal sheets were then carefully separated from epidermal 
sheets, cut into small pieces of 1 – 5 mm, and enzymatically 
 digested with a mixture containing collagenase and hyaluronidase 
type VII (each at 200 U/mL; both from Sigma-Aldrich Schweiz, 
Buchs, Switzerland), 0.01% DNase I (Roche Diagnostics), 1 m M 
sodium pyruvate, 1% antibiotic-antimycotic mixture (containing 
penicillin at 10  000 U/mL, streptomycin at 10  000  μ g/mL, and 
 amphotericin B at 25  μ g/mL in a solution of 0.85% NaCl), and 
10 m M HEPES buffer (all from Gibco Invitrogen AG, Basel, 
Switzerland) for 2 hours at 37 °C to obtain single-cell suspen-
sions. Three-color staining for fl ow cytometry was performed 
by using FITC-conjugated anti-BDCA-2 and allophycocyanin-
 conjugated CD123 (both from Miltenyi Biotec) and  phycoerythrin-
conjugated antibodies against CD3, CD11c, CD14, CD20, CD56, 
CD80, CD86, or HLA-DR or their corresponding isotype controls 
(all from BD Biosciences). For intracellular IFN- α  detection, cells 
were fi rst surface stained with FITC-conjugated anti-BDCA-2 an-
tibodies, permeabilized with 0.1% saponin in phosphate-buffered 
saline, and then stained with phycoerythrin-labeled anti-human 
IFN- α 2 antibody (225.C, Chromaprobe Inc., Maryland Heights, 
MO) or IgG2b isotype control. Cells were then analyzed on a 
FACSCalibur fl ow cytometer, and data were processed with 
 CellQuestPro software (both BD Biosciences). 
 Statistical Analysis 
 Quantitative immunohistochemistry data were expressed as 
the median number of cells per ×40 fi eld. For the quantitative 
 immunohistochemistry analysis, pairs missing respective pre-
treatment marker evaluation were excluded from matched 
 statistical analysis (Wilcoxon test and Spearman’s correlation). 
Statistical analysis was performed with the SPSS software pack-
age, version 12.0 (SPSS, Chicago, IL).  P values of less than .05 
were considered statistically signifi cant. All statistical tests were 
two-sided. 
 R ESULTS 
 Characterization of the Imiquimod-Induced Changes in 
Gene Expression Profi les of Skin Tumors 
 To investigate the effects of topical imiquimod treatment on 
gene expression profi les of neoplastic epithelial and lymphopro-
liferative diseases of the skin, we generated gene expression 
 profi les from specimens obtained before and after treatment with 
imiquimod from the following lesions: 11 sBCC lesions (from 
10 patients, one of whom had two treated lesions), fi ve CTCL 
 lesions, and one Bowen’s disease lesion. By using our fi ltering 
criteria, we found 709 genes that were differentially expressed 
in response to topical imiquimod treatment; expression of 366 
genes was increased, and expression of 343 genes was decreased. 
We subjected this set of 709 differentially regulated genes to two-
way hierarchical clustering analysis, which is a mathematical 
 approach that essentially organizes the data by grouping genes 
with similar expression patterns. This analysis identifi ed two 
 major array clusters associated with imiquimod treatment —
 pretreatment and posttreatment clusters ( Fig. 1, A ). 
 To facilitate the analysis of genes that account for differ-
ences in overall gene expression, each gene was assigned to a 
defi ned functional category according to available annotations 
(i.e., a GO search on the NetAffx website,  http://www.affymetrix. 
com/analysis/index.affx ). We found that one third of the genes 
whose expression was stimulated by imiquimod were  involved 
in various aspects of immune response ( Fig. 2 ). A series of IFN-
 α – inducible genes including CIG5, G1P2, OASL, IFIT1, STAT1, 
IFI35, OAS1, ISG20, MxA, and IRF7, the so-called IFN- α 
 signature, was the most prominently induced by imiquimod 
( Fig. 2 ). Imiquimod treatment stimulated the expression of these 
IFN-inducible genes in both sBCCs and CTCLs ( Fig. 1, A ). 
 According to the clustering analysis, the expression of two IFN-
 α – inducible genes, IRF7 and MxA, was not increased in three 
imiquimod-treated samples (CTCL1, CTCL2, and CTCL3). To 
investigate the differences in IRF7 and MxA mRNA levels 
 between samples before and after imiquimod treatment, we used 
real-time PCR to assess the expression of these two genes, which 
are highly specifi c for local IFN- α activity. When we compared 
the array data and the PCR data for the expression of IRF7 and 
MxA, we found good correlation (for IRF7 expression, Pearson’s 
 r = .679 and  P <.001; for MxA expression Pearson’s  r = .501 and 
 P = .005). Real-time PCR analysis confi rmed the increased 
 expression of IRF7 and MxA genes in all imiquimod-treated 
 tumors, including tumors CTCL1, CTCL2, and CTCL3,  compared 
with expression before treatment, irrespective of the disease type 
( Fig. 1, B ). Immunohistochemistry also demonstrated consis-
tently increased MxA protein expression in all imiquimod-treated 
tumors (data not shown), supporting the array data. 
 Recruitment of PDCs Into the Skin After 
Imiquimod Treatment 
 The distinct, disease-independent imiquimod-related expres-
sion of IFN- α – inducible genes raised the question of whether 
these results refl ected the imiquimod-induced accumulation of 
PDCs in the treated lesions. First, microarray data indicated that 
PDCs may be present in BCC, CTCL, and Bowen’s disease 
 lesions because of the increased expression of several genes 
 expressed by PDCs, including CD123 (IL3R α )  ( 5 ) , CD38  ( 17 ) , 
CD62L (L-selectin)  ( 7 ) , ILT3  ( 7 ) , ILT7  ( 23 ) , and CD43  ( 24 ) 
 after imiquimod treatment ( Fig. 2 ). Second, we used an antibody 
specifi c for blood PDCs (i.e., anti-BDCA-2 antibody)  ( 25 ) and 
an antibody against CD123 (IL3R α ), which is highly expressed 
on PDCs, to determine whether PDCs were present in lesions 
before and after imiquimod treatment. Eleven  “ baseline to post-
treatment ” matched samples (fi ve BCCs, fi ve CTCLs, and one 
Bowen’s disease) were available for matched quantitative 
 immunohistochemistry analysis of BDCA-2 and CD1c markers, 
and 16 matched pairs were available for quantitative immuno-
histochemistry analysis of CD123. We found that the number of 
BDCA-2 +  cells in skin lesions was statistically signifi cantly 
higher after imiquimod treatment (from a median of 1.2 cells per 
×40 fi eld before imiquimod treatment to a median of 28.0 cells 
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 Fig. 1. Gene expression profi ling of skin tumors treated with cream containing 
5% imiquimod.  A ) Interferon (IFN) clusters obtained after hierarchical clustering 
analysis of 709 differentially expressed genes. Relationship between experimental 
samples is summarized in a dendrogram above the microarray, in which the 
pattern and the length of the branches refl ect the relatedness of the samples. 
 Red = high relative level of expression;  green = low relative level of expression; 
 black branches = samples before imiquimod treatment;  blue branches = samples 
after imiquimod treatment. Genes are identifi ed by their GenBank accession 
number and symbol. To the right of each gene symbol, changes in relative 
gene expression levels are represented by bars showing fold change increase in 
expression after treatment.  Blue bars = IFN- α – inducible genes;  black bars = 
IFN- γ – inducible genes. Names of pretreatment samples are followed by  “ _0 ” ; 
names of posttreatment sample names are followed by  “ _post ” .  B ) Expression 
of MxA and IRF7 mRNA obtained by microarray analysis ( bars ) and by real-
time polymerase chain reaction (PCR; LightCycler;  triangles ). Microarray gene 
expression data are expressed as signal intensity ( y axis to the  right ). PCR results 
(the means of triplicate experiments are expressed as the copy number (i.e., as 
glyceraldehyde-3-phosphate dehydrogenase [GAPDH] – normalized ratios to 
compensate for variations in quantity and quality of starting mRNA) ( y axis to 
the  left ). Low variability between triplicate experiments gave error bars (95% 
confi dence intervals) that were too small to be visualized beyond the symbols. 
Pretreatment samples are shown as  open bars ( triangles ), whereas posttreatment 
samples are shown as  shaded bars ( black triangles ). BCC = basal cell carcinoma; 
CTCL = cutaneous T-cell lymphoma; MB = Bowen’s disease. 
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per ×40 fi eld after imiquimod treatment; the median difference 
among 11 matched samples of BDCA-2 +  cells = 26.8 cells per 
fi eld;  P = .003, Wilcoxon test;  Figs. 3 and  4, A ) than before 
 treatment. Results were similar regardless of whether the lesion 
was from an epithelial disease group (sBCC and Bowen’s dis-
ease) or a lymphoproliferative disease group (CTCL) ( Fig. 3, B ). 
The number of CD123-expressing cells increased statistically 
 signifi cantly also after imiquimod treatment (from a median of 
2.3 cells per ×40 fi eld before imiquimod treatment to a median 
of 39.3 cells per ×40 fi eld after imiquimod treatment; the median 
difference among 16 matched samples of CD123 +  cells = 37 
cells per fi eld;  P <.001, Wilcoxon test). The PDC phenotype was 
confi rmed by costaining BDCA-2 +  cells with antibodies against 
CD123 and CD4, antigens that are coexpressed by PDCs, and 
viewing with confocal laser-scanning microscopy ( Fig. 4, B and 
C ). In addition, fl ow cytometry analysis of dermal cell suspen-
sions revealed that BDCA-2 + ,CD123 ++  cells were also HLA-
DR + ,CD11c −  but did not express the lineage markers CD3, 
CD14, CD20, and CD56; this phenotype corresponds to the PDC 
phenotype ( Fig. 5, B ). CD4 was not assessed by fl ow cytometry, 
because the treatment with dispase and collagenase disrupts 
CD4 cell surface expression so that it is undetectable  ( 26 ) . 
 According to fl ow cytometry analysis, PDCs accounted for up to 
16.4% of the dermal mononuclear infi ltrate (mean = 6.4%, 95% 
confi dence interval [CI] =  − 0.2% to 13%; range = 2.2% – 16.4%; 
 n = 4 lesions). 
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 Immunohistochemistry and confocal microscopy revealed 
that PDCs preferentially localized subepidermally, even though 
small groups of BDCA-2 + ,CD123 +  cells could be observed in the 
vicinity of blood vessels or tumor islets ( Fig. 4, B and C ). To 
 assess the alterations in dermal dendritic cells of myeloid origin 
(MDCs) in skin lesions before and after imiquimod treatment, we 
used quantitative immunohistochemistry for an MDC-specifi c 
marker, CD1c. Unlike PDCs, the number of CD1c +  MDCs in the 
lesions was not changed by imiquimod treatment (i.e., a median 
of 33.5 cells per ×40 fi eld before treatment to a median of 35.5 
cells per ×40 fi eld after treatment; the median difference among 
11 matched samples of CD1c +  cells = 2.0 cells per fi eld;  P = .477, 
Wilcoxon test;  Fig. 3 ). 
 Furthermore, we found that the increase in the number of 
PDCs (BDCA-2 +  and CD123 +  cells) from baseline to posttreat-
ment was accompanied by a statistically signifi cant increase in 
infi ltrate density grade (for BDCA-2 Spearman’s  ρ = .717 and 
 P <.001; for CD123 Spearman’s  ρ = .766 and  P <.001), thus indi-
cating that PDCs along with other infl ammatory cells are being 
actively recruited into the treated lesion ( Fig. 3, C ). The active 
recruitment of these cells into imiquimod-treated lesions is also 
supported by a 173-fold increase (range = 2.3-fold to 1232.9-fold 
increase) in expression in lesions of the CXCL11/ITAC gene, 
a chemokine that is involved in the recruitment of the PDC to 
 infl amed skin  ( 27 ) , compared with levels before treatment 
( Fig. 2 ). Changes in MDC (CD1c + ) cell numbers, however, did 
not correlate with the changes in infi ltrated density grade, sup-
porting their  “ resident ” nature in the dermis (Spearman’s 
 ρ = .245 and  P = .227). 
 Skin-Infi ltrating PDCs and the Production of IFN- α 
After Imiquimod Treatment In Vivo 
 In vitro, PDCs produce large amounts of IFN- α in response to 
imiquimod treatment  ( 15 ) . To determine whether skin-infi ltrating 
PDCs also produce IFN- α after topical imiquimod treatment in 
vivo, we analyzed single-cell suspensions of dermal cells  isolated 
from skin biopsy specimens of four sBCCs treated for 5 days 
with imiquimod. By intracellular staining with an antibody 
against IFN- α , up to 27% of BDCA2 + ,CD123 ++  PDCs produced 
IFN- α (mean = 14.5%, 95% CI = 4.9% to 24.0%; range = 3.3% –
 27%,  n = 4 lesions  Fig. 5, C ). In contrast, no other dermal cell 
types (BDCA-2 − ,CD123 −  cell population) produced detectable 
amounts of IFN- α (<1%,  n = 4 lesions), indicating that PDCs are 
the principal producers of IFN- α in imiquimod-treated lesions in 
vivo ( Fig. 5, C ). 
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 Fig. 3 . Quantitative immunohistochemistry data. Data are 
expressed as the median number of cells expressing the 
respective marker per ×40 fi eld.  A) Expression of BDCA-2, 
CD123, and CD1c cell surface proteins in cells of skin tumors 
obtained before and after topical imiquimod treatment.  B) 
Expression of BDCA-2, CD123, and CD1c cell surface 
proteins in skin tumors obtained before and after topical 
imiquimod treatment according to the disease histology. 
 C) Expression of BDCA-2, CD123, and CD1c cell surface 
proteins in skin tumors obtained before and after topical 
imiquimod treatment according to infi ltrate density grade. 
 A – C) Horizontal lines = median cell count for each marker; 
 open circles = before treatment;  open triangles = after 
treatment.  A and B) Statistical signifi cances of differences 
between pretreatment and posttreatment marker expression 
are indicated with an asterisk (*); the corresponding  P value 
shown below each graph (two-sided Wilcoxon signed rank 
test).  C) Two-sided Spearman’s  ρ and corresponding  P values 
are shown below each graph (Spearman’s rank correlation). 
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 Role of PDCs in the Clinical and Transcriptional 
Response to Imiquimod 
 To determine whether PDCs or other types of cells, such as 
MDCs, were shaping the gene expression profi le of the skin 
 lesions in response to imiquimod treatment, we next compared the 
number of PDCs (i.e., BDCA-2 +  cells) and MDCs (i.e., CD1c +  
cells) with the expression of various IFN-inducible genes detected 
by the Affymetrix arrays in skin lesions treated with  imiquimod. 
The number of PDCs correlated (by the Spearman’s correlation 
test) with the level of expression of known IFN- α – inducible 
genes (IRF7, Spearman’s  ρ = .542 and  P = .004; MxA,  ρ = .440 
and  P = .024; G1P2,  ρ = .751 and  P <.001; G1P3,  ρ = .652 and 
 P <.001; OASL,  ρ = .728 and  P <.001; IFI35,  ρ = .720 and  P <.001; 
ISG20,  ρ = .718 and  P <.001; IFIT1,  ρ = .705 and  P <.001; CIG5, 
 ρ = .688 and  P <.001; OAS1,  ρ = .405 and  P = .04; STAT1,  ρ = 
.532 and  P = .005; and IFI44,  ρ = .608 and  P = .001) and with the 
level of expression of genes for various chemokines, cytokines, 
and their receptors (CXCL11,  ρ = .698 and  P <.001; CCL8,  ρ = 
665 and  P <.001; IL6,  ρ = .646 and  P <.001; CCL5,  ρ = .539 and 
 P = .005; CCL2,  ρ = .550 and  P = .004; CCL3,  ρ = .622 and  P = 
.001; CCL4,  ρ = .419 and  P = .033; IL18-RAP,  ρ = .535 and  P = 
.005; CXCR4,  ρ = .523 and  P = .006; and CD123/IL3RA,  ρ = .625 
and  P = .001). In contrast, the number of CD1c +  cells did not 
 correlate with the expression of any of these genes. 
 We fi nally examined gene expression in the three tissue sam-
ples that were not assigned to the correct array group by the 
 hierarchical clustering algorithm. Gene expression patterns of 
two samples treated with imiquimod (lesions BCC4 and BCC7) 
clustered with that of the pretreatment samples, and gene 
 expression patterns of one untreated sample (lesion CTCL2) 
clustered with that of posttreatment samples. Lesions BCC4 and 
BCC7 had fewer PDCs after imiquimod treatment ( Table 1 ). In 
addition, imiquimod treatment of lesion BCC4 did not result in 
an infl ux of infl ammatory cells to the lesion (i.e., no increase 
of  infi ltrate density grade). Even though the infi ltrate density 
 Fig. 4. In situ identifi cation of plasmacytoid predendritic cells (PDCs) in 
the dermal infi ltrate of a basal cell carcinoma treated with imiquimod.  A ) 
Immunohistochemical staining for the PDC-specifi c marker BDCA-2. Numerous 
BDCA-2 +  cells ( red ) recruited to the treatment site are shown (original 
magnifi cation = ×20). For better discrimination of the infi ltrate, tumor borders 
are indicated by  dotted lines. Arrowhead = epidermis.  B and  C ) Confocal 
laser-scanning microscopy of the co-expression of BDCA-2 ( green ), CD123 
( red ), and CD4 ( blue ) cell surface proteins on dermal PDCs.  B ) Co-staining for 
BDCA-2 and CD123 =  yellow (magnifi cation = ×40).  C ) Co-staining for BDCA-
2 and CD4 =  turquoise (original magnifi cation = ×20).  White arrowheads = 
epidermis.  Scale bar = 50  μ m. 
 Fig. 5.  Flow cytometry quantifi cation of plasmacytoid predendritic cells (PDCs) 
in dermal cell suspensions.  A ) PDCs stained with anti-BDCA-2 and anti-CD123 
antibodies in basal cell carcinoma (BCC) treated with imiquimod. The  round 
gate shows the percentage of cells expressing BDCA-2 and CD123 surface 
markers.  B ) Marker expression in imiquimod-treated PDCs. After treatment 
with imiquimod, dermal PDCs from a BCC were stained with antibodies against 
HLA-DR, CD80, or CD86 or with antibodies against the lineage markers CD3, 
CD11c, CD14, CD20, or CD56. Isotype-matched control antibody =  shaded 
histogram ; BDCA-2 + , CD123 +  cells =  solid black line .  C ) Flow cytometry 
analysis of intercellular interferon (IFN)  α 2 and BDCA-2 protein expression in 
PDCs in dermal cell suspensions. PDCs were stained with antibodies against 
IFN- α 2 or with the isotype control (IgG2b). PDC = cells gated for BDCA-2 
and CD123 expression shown in the  A . Non-PDCs = all other nongated cells 
shown in  A . 
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IFN- α production in mice treated with imiquimod, much effort 
has been directed at identifying the primary cellular target(s) for 
imiquimod and other imidazoquinolines in humans  ( 14 , 15 , 28 , 29 ) . 
Of the 11 described members of the TLR family, human PDCs 
express only TLR7 and TLR9  ( 30 ) . After many reports on the 
induction of IFN- α production after imiquimod treatment  ( 14 , 15 , 
 29 , 31 – 35 ) , it was shown  ( 36 , 37 ) that natural IFN- producing cells 
(also known as PDCs) express a TLR that is activated by imiqui-
mod — a link that was missing for almost a decade was found. 
grade increased in lesion BCC7, only single PDCs that were 
dispersed through the dermis were observed. Despite the allo-
cation of the imiquimod-treated BCC7 to the pretreatment 
group, the expression of a series of IFN- α – but not IFN- γ –
 inducible genes was stimulated by imiquimod treatment 
( Fig. 1, A ), suggesting the minimal activation of single PDCs 
present in the lesion (i.e., IFN- α – inducible genes) but no down-
stream activation of the T helper type 1 immune response 
(i.e., IFN- γ – inducible genes). In contrast, in lesion BCC4, the 
expression of neither group of IFN-inducible genes increased 
after imiquimod treatment ( Fig. 1, A ), indicating a complete 
lack of responsiveness to imiquimod treatment. This lack of 
 response was also observed clinically; no infl ammatory reac-
tion (i.e., redness, edema, or scaling) was  observed for lesions 
BCC4 and BCC7 during imiquimod treatment ( Fig. 6 ). How-
ever, an infl ammatory reaction was observed for lesion CTCL2, 
in which the gene expression profi le of samples before and after 
imiquimod treatment clustered with the  imiquimod-treated 
group. One explanation for this unusual array pattern may be in 
the fact that lesion CTCL2 had an increased number of BDCA2 +  
cells and an unusually high number of CD1c +  cells before 
treatment ( Table 1 ). 
 D ISCUSSION 
 Our current study shows that, irrespective of whether the 
 tumor was BCC, CTCL, or Bowen’s disease, imiquimod  induced 
a gene expression profi le in these tumors that is reminiscent of 
activated PDCs and is related to the number of PDCs recruited to 
the treatment site. Our results also show that PDCs are the pri-
mary source of IFN- α in skin lesions in response to imiquimod 
treatment. In patients who did mount a clinical  infl ammatory 
 reaction in response to imiquimod treatment, the IFN- α gene sig-
nature was not observed in treated lesions and fewer PDCs were 
detected in treated lesions than in other treated lesions that 
showed a clinical infl ammatory reaction. Thus, PDCs appear to 
have a role in the clinical response to imiquimod. 
 Since Hemmi et al.  ( 13 ) reported activation of the Toll-like 
receptor 7 (TLR7)/MyD88 signaling pathway and increased 
 Fig. 6.  Infl ammatory reaction and gene expression before and after imiquimod 
treatment.  A ) Infl ammatory reaction (redness, edema, and swelling) often 
observed clinically after 5 days of topical imiquimod treatment. A basal cell 
carcinoma (BCC) lesion, SCC8, is shown that was classifi ed as a responder by 
array analysis.  B, C ) Lack of infl ammatory reaction in two BCC lesions, BCC4 
and BCC7, that were classifi ed as nonresponders according to array analysis. 
 Scale bar = 1 cm. 
 Table 1.  Quantitative immunohistochemistry of BDCA-2, CD123, and CD1c expression in skin tumors before and after topical imiquimod treatment 
  No. of positive cells per ×40 fi eld  
  BDCA2  CD123  CD1c  Infi ltrate grade 
 Lesion *  Before  After  Before  After  Before  After  Before  After 
 BCC1  21  86  4  123  56  57  2  3 
 BCC2  —  94  3  51  —  52  1  3 
 BCC3  3  34  1  48  10  36  1  3 
 BCC4  1  12  0  3  17  15  1  1 
 BCC5  —  29  0  41  —  47  1  2 
 BCC6  —  —  0  31  —  —  1  3 
 BCC7  4  6  9  9  28  30  1  3 
 BCC8  0  91  4  93  16  45  1  3 
 BCC9  —  21  13  54  —  20  1  3 
 BCC10  —  20  12  45  —  15  2  3 
 CTCL1  3  28  2  62  37  20  1  3 
 CTCL2  17  45  10  12  140  101  2  3 
 CTCL3  0  18  0  38  16  33  1  3 
 CTCL4  1  15  0  32  90  62  1  3 
 CTCL5  0  2  0  3  103  66  2  3 
 MB  1  64  12  32  34  16  1  3 
 * BCC = basal cell carcinoma; CTCL = cutaneous T-cell lymphoma; MB = Bowen’s disease;  — = not done due to the lack of material. 
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However, the question remained that, if PDCs are the  primary 
target cells for imiquimod in the blood, are PDCs the primary 
target for imiquimod in the skin lesions? Recently Palamara et al. 
 ( 38 ) observed the accumulation of PDC-like cells in the dermis 
of melanoma-bearing mice topically treated with  imiquimod. We 
have demonstrated, to our knowledge for the fi rst time, that PDCs 
(i.e., Lin − , BDCA-2 + , CD123 + , CD4 + , and HLA-DR +  cells) are 
recruited to cutaneous epithelial and lymphoproliferative tumors 
treated with imiquimod. PDC recruitment by imiquimod treat-
ment was further supported by gene expression profi les showing 
that the expression of a set of genes that are known to be ex-
pressed by PDCs was consistently increased in lesions treated 
with imiquimod. PDCs accounted for up to 16% of dermal mono-
nuclear cells in sBCC lesions treated with imiquimod, which is 
more than 10 times higher than the reported frequency (0.10% –
 0.30%) of PDCs among peripheral blood mononuclear cells 
 ( 6 , 7 ) . This increase in the number of PDCs at the treatment site 
appeared to be independent of the underlying type of skin tumor 
evaluated in this study, supporting the specifi city of the TLR re-
sponse to a synthetic ligand, such as imiquimod  ( 3 ) . Even though 
some tissue samples used in the microarray analysis were not 
available for the matched immunohistochemistry analysis (fi ve 
of the total 16 samples; i.e., fi ve of 10 sBCC), there was clear 
evidence of recruitment and accumulation of PDCs to the lesions 
after topical imiquimod treatment in the evaluated tumor groups. 
After the PDCs have migrated into the skin, they probably 
 respond to either the imiquimod gradient at the entry point or the 
chemokine gradient induced by imiquimod, as refl ected in their 
preferential grouping in the subepidermal zone of the area treated 
with imiquimod cream. 
 Furthermore, in contrast to other dermal cell populations, we 
found that PDCs recruited to the imiquimod-treated lesions were 
the principal producers of IFN- α . Each functional blood PDC is 
capable of producing 1 – 2 IU (3 – 10 pg) of IFN- α  ( 6 , 7 , 39 ) . If we 
extrapolate this amount of IFN- α to that produced by at least 
10  000 PDCs — the number of cells that we detected by fl ow 
 cytometry in an excised imiquimod-treated BCC — then 1000 IU 
of IFN- α would be produced by PDCs in 2 – 3 cm 3  of skin. This 
level of IFN- α appears to specifi cally shape the gene expression 
signature in both epithelial and lymphomatous lesions treated 
with imiquimod. As we previously reported  ( 17 ) , various IFN-
 α – responsive genes were induced in all treated samples. In three 
CTCL samples, we found almost no change in the expression of 
IRF7 and MxA genes before and after imiquimod treatment, as 
 detected by microarrays. However, by using real-time PCR (a 
more sensitive method than arrays), we found that the expression 
of IRF7 and MxA genes in these three CTCL lesions and in other 
tumors was increased by imiquimod treatment. IRF7 is a transcrip-
tion factor constitutively expressed in PDCs  ( 40 ) . IRF7 appears to 
be the key regulator in TLR7-mediated IFN- α induction or produc-
tion through formation of a complex with MyD88 and TRAF6 
 ( 41 ) . Induction of IRF7 gene expression by imiquimod treatment 
could, therefore, be refl ected by an increase in the number of 
PDCs or the induction of IRF7 in other cell types in the lesion by 
IFN- α  ( 42 , 43 ) . 
 Activation of TLR7 by imiquimod results in the production 
of IFN- α and other type I IFNs  ( 13 , 15 ) , which in turn drives 
adaptive immunity toward a T helper type 1 immune response, 
either directly through the induction of IFN- γ in T cells or indi-
rectly through the promotion of dendritic cell maturation [for 
review, see  ( 3 , 4 ) ]. The importance of IFN- α in initiating each of 
these downstream events is refl ected in the lack of expression of 
many directly or indirectly IFN- α – inducible gene products in 
the two patients who did not respond to imiquimod treatment 
in our study and in other studies  ( 44 – 46 ) . In addition to fewer 
PDCs, these two patients did not have a clinical infl ammatory 
response, suggesting that their inability to respond to imiquimod 
(induction of IFN- α -responsive genes or a clinical response) 
may be the result of insuffi cient or impaired PDC recruitment to 
the treatment site. 
 Previous clinical studies have demonstrated a correlation 
 between the regression of viral warts or high-grade intraepithe-
lial neoplasia treated with imiquimod and the induction of IFN- α , 
IFN- γ , STAT1, and 2 ′ –5 ′ oligoadenylate synthetase gene expres-
sion  ( 44 – 46 ) . In patients with genital warts treated with imiqui-
mod, erythema at the treatment site correlated with the expression 
of IFN- γ , CCL5/RANTES, and CCL2/MCP-1 genes  ( 44 ) .  Neither 
of the sBCC lesions studied that displayed no infl ammatory reac-
tion to imiquimod treatment showed increased expression of any 
of these genes (data not shown). However, we found good cor-
relation between expression levels of IFN- α – inducible genes and 
the number of PDCs in all lesions, consistent with a role for 
PDCs in mediating the clinical response (generally painless 
 infl ammation) to imiquimod treatment. A recent study  ( 38 ) in a 
melanoma mouse model also supports this result, by showing 
that the regression of the tumors treated with imiquimod corre-
lated with the number of PDC-like cells recruited to the treated 
lesion. 
 When we further examined the expression of CXCL11, a 
 chemokine that participates in PDC recruitment to infl amed skin 
 ( 27 ) , we found that CXCL11 expression in these two nonre-
sponders was not increased by imiquimod treatment. CXCL11/
ITAC binds to CXCR3 (which is highly expressed on PDCs) and, 
in response to CXCL12/SDF-1, induces the recruitment of PDCs 
into the skin  ( 27 ) . After imiquimod treatment, we also observed 
the increased expression of CXCR4, a cognate receptor for 
CXCL12/SDF-1 that is expressed at a high level on PDCs  ( 27 , 47 ) . 
Even though the CXCL12/SDF-1 gene was expressed in samples 
before and after imiquimod treatment, its expression did not pass 
our fi ltering criteria, refl ecting the fact that CXCL12/SDF-1 is 
constitutively expressed on dermal endothelial cells  ( 48 ) . CXCR3 
cell surface expression is rapidly lost after PDC stimulation 
 because PDCs begin to secrete high levels of CXCR3 ligands and 
other chemokines  ( 49 ) . Inhibition of the expression of CXCR3 
by the autocrine secretion of the CXCR3 agonists (such as 
CXCL9, CXCL10, and CXCL11) is probably the reason that we 
did not observe the increased expression of CXCR3 in the array 
data. The genes CCL2/MCP1, CCL3/MIP-1 α , CCL4/MIP-1 β , 
CCL5/RANTES, and CCL8/MCP-2, whose expression was 
 increased after imiquimod treatment, encode key chemokines 
produced in response to an active microbial infection of TLR 
triggering with a single goal to recruit infl ammatory cells to the 
site of infection or for imiquimod treatment to the treatment site 
 ( 3 , 12 , 50 ) . This massive production of various chemoattractants 
is particularly refl ected in the rapid increase in the skin infi ltrate 
density grade that we observed at the treatment site after 5 days 
after treatment was initiated. We found that the number of PDCs 
increased accordingly, suggesting that these cells and other 
 infl ammatory cells were being recruited. PDCs and MDCs  appear 
to be capable of producing various chemokines, including CCL2/
MCP1, CCL3/MIP-1 α , CCL4/MIP-1 β , and CCL5/RANTES, in 
response to bacterial or viral antigens and CpG motifs  ( 49 , 51 , 52 ) . 
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Through the production of chemokines, PDCs may also be 
 contributing to the early recruitment of other infl ammatory cells 
to the treatment site. 
 The mechanism that triggers or induces the active recruit-
ment of PDCs and other infl ammatory cells to the skin in 
 response to imiquimod remains elusive. Cells in the skin that are 
the primary target for imiquimod and thus a primary source of 
various PDC-chemoattracting substances remain to be defi ned. 
It is known that keratinocytes produce cytokines other than 
IFN- α in response to imiquimod treatment  ( 53 ) , even though 
they do not express TLR7  ( 54 ) . Epidermal Langerhans cells do 
not  express TLR7 either  ( 55 ) . TLR7 expression on MDCs re-
mains controversial, despite evidence of low TLR7 expression 
on MDCs  ( 30 ) and evidence that MDCs produce interleukin 12 
in response to imiquimod treatment  ( 14 ) . It is conceivable that a 
high local concentration of imiquimod may be suffi cient to 
 activate MDCs in a TLR8-dependent manner, given the high 
structural similarity between TLR7 and TLR8  ( 56 , 57 ) and the 
fact that imiquimod and other similar TLR7 agonists are not 
necessarily TLR7-specifi c agonists. A recent report  ( 58 ) describ-
ing the induction of TLR7 expression on MDCs by IFN- α 
 suggests that in vivo MDCs and PDCs may coordinate their 
 responses to imiquimod. Whether any of these cells or any other 
cells with yet undiscovered TLRs represent primary targets for 
imiquimod remains to be elucidated. 
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